BioSpace News Archive

Orca Bio announced positive new data that suggest its investigational high-precision cell therapies, Orca-T and Orca-Q, have the potential to deliver improved clinical outcomes across different age ranges, donor types and conditioning regimens relative to existing standard of care allogeneic hematopoietic stem cell transplants.

Aptose Biosciences Inc. announced that a growing body of clinical data for Aptose’s lead compound tuspetinib, demonstrates significant benefit as a single agent and in combination with venetoclax in patients with relapsed or refractory acute myeloid leukemia in the ongoing APTIVATE Phase 1/2 study.

Agios Pharmaceuticals, Inc. presented detailed results from the Phase 2 portion of the global RISE UP study of mitapivat in sickle cell disease in an oral presentation at the 65th American Society of Hematology Annual Meeting & Exposition, which is being hosted Dec. 9-12, 2023, in San Diego.

Pfizer Inc. presented results from the pivotal Phase 3 BASIS clinical trial evaluating marstacimab for the treatment of people with severe hemophilia A and moderately severe to severe hemophilia B without inhibitors to Factor VIII or Factor IX.

Nkarta, Inc. announced a poster presentation at the 2023 American Society of Hematology Annual Meeting and Exposition featuring follow-up data from its Phase 1 clinical trial that evaluates NKX101 in patients with relapsed or refractory acute myeloid leukemia.

Four studies presented during the 65th American Society of Hematology Annual Meeting and Exposition examine how demographics and other characteristics of patients and researchers play into inequities in health outcomes in the context of blood cancers.

Researchers report striking progress in the application of cutting-edge tools and treatments to address longstanding challenges in blood disorders and related health conditions in four studies presented during the 65th American Society of Hematology Annual Meeting and Exposition.